Medication Guide

Prescription Info

Instructions for Use

Treating patients on HUMIRA (adalimumab)? Consider a biosimilar called HADLIMA. HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
Limitations of Use:
The effectiveness of HADLIMA has not been established in patients who have lost response to or were intolerant to tumor necrosis factor (TNF) blockers. Dov, a real patient with moderately
to severely active ulcerative colitis who switched from HUMIRA (adalimumab)
to HADLIMA, an FDA-approved interchangeable biosimilar to HUMIRA. Cost and coverage for HADLIMA
is dependent on the terms and
conditions of individual insurance
benefits, including any applicable deductible, co-insurance, or co-payment.Based on analysis of actual patient
claims processed from July 2023
to August 2024, with the average
out-of-pocket costs being $215 vs $48
for HUMIRA and HADLIMA, respectively. Consider which patients
may benefit from switching
to HADLIMA today.